News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Amplia.
RELATED STOCKHEAD STORIES
Health & Biotech
Investors’ sneak peek at biotech’s bright future
Health & Biotech
ASX Health Stocks: Island to tackle deadly Ebola virus
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
ASX Health Stocks: Argenica’s traumatic brain injury drug works well in animal model
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Amplia gets FDA green light to commence trial; Recce study meets all primary endpoints
Health & Biotech
ASX Health Stocks: Imugene gains on positive early signs from Phase 1 trial
News
Market Highlights: Wall Street falls on Fedspeak, the most crowded trades, and 5 ASX small caps to watch
Health & Biotech
ASX Health Stocks: Amplia’s pancreatic cancer trial gets boost; Emyria’s MDMA therapy is one step closer
Health & Biotech
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
News
In Case You Missed It: Bumper software revenue, a lithium farm-in and CSIRO research partnership
News
Market Highlights: Debt ceiling climax weighs on markets, Albanese brings home the bacon from G7
Health & Biotech
ASX Health Stocks: Antisense commences trial dosing, Shine lawyers deliver historic $300m settlement
News
Closing Bell: With great power comes a carefully nuanced distancing from responsibility; the ASX is flat too
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
ASX Health Stocks: Alterity is set to launch Phase 2 clinical trial on Multiple System Atrophy
News
